Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth
Avidity plans to initiate global Phase 3 HARBOR™ trial of AOC 1001 for DM1 mid-2024
Company to report data from all three ongoing clinical programs in 2024
— AOC 1001 data for DM1 in Q1, AOC 1020 data for FSHD in Q2, and AOC 1044 data for DMD44 in 2H —
Related news for (RNA)
- Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock
- Avidity Biosciences Announces Proposed Public Offering of Common Stock
- Avidity Biosciences’ Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44
- Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission